Idorsia Ltd
Clinical Research Study With Clazosentan to Evaluate Its Effects on Preventing Complications Due to the Narrowing of the Blood Vessels (Vasospasm) in the Brain, Caused by Bleeding Onto the Surface of the Brain
- Conditions
- Aneurysmal Subarachnoid Hemorrhage
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-07-12
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 409
- Registration Number
- NCT03585270
- Locations
- 🇺🇸
University of Illinois - Department of Neurosurgery, Chicago, Illinois, United States
🇺🇸University Hospitals Case Medical Center - Department of Neurosurgery, Cleveland, Ohio, United States
🇭🇺Debreceni Egyetem, Idegsebészet, Debrecen, Hungary
Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep
- First Posted Date
- 2018-07-02
- Last Posted Date
- 2022-03-25
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 924
- Registration Number
- NCT03575104
- Locations
- 🇨🇦
Canadian Phase Onward Inc., Toronto, Ontario, Canada
🇺🇸FutureSearch Trials of Neurology, LP, Austin, Texas, United States
🇺🇸Neurotrials Research Incorporated, Atlanta, Georgia, United States
Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects With Insomnia Disorder
- Conditions
- Insomnia Disorder
- Interventions
- First Posted Date
- 2018-06-04
- Last Posted Date
- 2022-03-25
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 930
- Registration Number
- NCT03545191
- Locations
- 🇺🇸
PAB Clinical Research, Brandon, Florida, United States
🇩🇪Klinische Forschung Hamburg GmbH, Hamburg, Germany
🇩🇪emovis GmbH, Berlin, Germany
A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety
- Conditions
- Resistant Hypertension
- Interventions
- First Posted Date
- 2018-05-30
- Last Posted Date
- 2023-03-21
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 730
- Registration Number
- NCT03541174
- Locations
- 🇺🇸
TLM Medical Services LLC, Columbia, South Carolina, United States
🇺🇸Academic Medical Research Institute Inc, Los Angeles, California, United States
🇺🇸California Kidney Specialists, San Dimas, California, United States
A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Heart Attack
- Conditions
- Acute Myocardial Infarction
- Interventions
- First Posted Date
- 2018-04-04
- Last Posted Date
- 2022-11-17
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT03487445
- Locations
- 🇮🇱
Galilee Medical Center, Nahariya, Israel
🇧🇪OLV Ziekenhuis Aalst, Aalst, Belgium
🇧🇪UZLeuven, Leuven, Belgium
A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2018-02-13
- Last Posted Date
- 2022-11-16
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 77
- Registration Number
- NCT03430661
- Locations
- 🇺🇸
Biotrial Inc, Newark, New Jersey, United States
Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease
- First Posted Date
- 2018-02-07
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 118
- Registration Number
- NCT03425539
- Locations
- 🇺🇸
Emory University School of Medicine; Department of Human Genetics, Atlanta, Georgia, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Research Baylor Institute of Metabolic Disease, Dallas, Texas, United States
A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Coronary Artery Disease
- First Posted Date
- 2017-12-28
- Last Posted Date
- 2022-11-17
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 346
- Registration Number
- NCT03384966
- Locations
- 🇺🇸
University of Florida (UF) Jacksonville, Jacksonville, Florida, United States
🇺🇸Florida Hospital Tampa - Pepin Heart Institute, Tampa, Florida, United States
🇺🇸NorthShore University, Chicago, Illinois, United States
Effect of Cimetidine on the Pharmacokinetics of Lucerastat in Healthy Subjects
- First Posted Date
- 2017-12-21
- Last Posted Date
- 2022-06-02
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT03380455
- Locations
- 🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Germany
A Study to Evaluate if ID-085 is Safe, Its Fate in the Body as Well as Its Potential Effects on the Body in Healthy Subjects
- First Posted Date
- 2017-12-13
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 88
- Registration Number
- NCT03372629
- Locations
- 🇬🇧
Covance Clinical Research Unit - Clinical Pharmacology Services, Leeds, United Kingdom